Allogeneic CAR-T Therapy Induces Immunosuppressant-Free Remission in Over Half of Lupus Patients in Phase 1 Trial

The U.S. Food and Drug Administration has authorized the biotechnology company Adicet Bio to advance an off-the-shelf cell therapy into a pivotal trial for severe lupus, aligning on an outpatient administration protocol that avoids mandatory hospital admission. The company will initiate the single-arm study in the fourth quarter of 2026, testing whether a one-time infusion of engineered immune cells can permanently reset the immune system in patients with lupus nephritis. The regulatory alignment follows early clinical data demonstrating that the therapy can drive the disease into remission without triggering the life-threatening inflammatory side effects that have recently derailed competing autoimmune programs.[2][3]

The investigational therapy, prulacabtagene leucel (prula-cel), is an allogeneic CAR-T treatment. Unlike autologous CAR-T therapies that require harvesting and genetically modifying a patient's own cells—a costly, highly personalized process that takes weeks to complete—prula-cel is manufactured from healthy donors and stored in advance. This off-the-shelf approach allows the therapy to be administered immediately upon prescription, significantly lowering the logistical barriers that have historically restricted cell therapies to specialized academic medical centers. For patients with rapidly progressing autoimmune conditions, bypassing the weeks-long manufacturing delay can prevent irreversible organ damage while the therapy is being prepared.[1][2]

The mechanism relies on a specific subset of immune cells called gamma delta T cells. Because these cells naturally home to and reside in body tissues rather than circulating in the bloodstream, researchers hypothesize they are better suited for autoimmune diseases that damage specific organs, such as the kidneys in lupus nephritis. Once infused, the gamma delta T cells migrate directly to the affected tissues to execute their engineered function, rather than triggering systemic immune responses throughout the circulatory system.[1]

The engineered cells are designed to hunt down and destroy cells expressing the CD20 protein. In systemic lupus erythematosus (SLE), CD20-positive B cells malfunction and produce autoantibodies that attack the patient's own tissues. By wiping out the errant B cells, the therapy forces the immune system to generate a new, naive population of B cells from scratch. This targeted depletion aims to eliminate the source of the autoimmune attack without permanently disabling the patient's ability to fight off future infections.[1]

"The B cells that come back after this reset, they come as naive B cells," Adicet CEO Chen Schor told Fierce Biotech following the data release. "These are B cells that are not associated with the disease, and that is really the definition of a reset." The return of these naive cells provides biological evidence that the therapy is not merely suppressing the immune system, but actively rebooting it to a healthy baseline state. This functional cure approach contrasts sharply with current standards of care, which rely on continuously dampening the entire immune response to keep lupus symptoms at bay.[1]

Phase 1 data, cut off on August 28, 2026, evaluated 22 highly pretreated patients, comprising 16 with lupus nephritis and six with extra-renal SLE. The cohort represented a severely ill population with limited remaining medical options; 71 percent of the participants had previously failed four or more standard therapies before enrolling in the trial. Despite their advanced disease state, all 22 efficacy-evaluable patients achieved undetectable levels of CD19-positive B cells following the infusion, confirming the therapy successfully executed its primary biological mechanism. Furthermore, 91 percent of the patients who tested positive for anti-dsDNA autoantibodies at baseline saw those destructive markers drop significantly.[3]

At the 12-month mark, 54 percent of evaluable patients achieved DORIS remission, a highly rigorous standardized clinical benchmark for systemic lupus. Among those specifically suffering from lupus nephritis, 50 percent achieved a complete renal response, indicating their kidney function had stabilized and the autoimmune organ damage had halted. These response rates surpass the historical benchmarks set by earlier personalized CAR-T treatments tested in lupus, providing strong validation for the off-the-shelf gamma delta approach. The clinical improvements were rapid and sustained, with the majority of patients maintaining their remission status through up to 21 months of continuous follow-up.[3][5]

Crucially, every patient in the efficacy cohort was able to discontinue their standard immunosuppressant medications following the treatment. All but one patient successfully tapered their background steroid use to five milligrams or less of prednisone equivalent per day. For patients accustomed to a lifetime of chronic immunosuppression and high-dose steroids—which carry severe long-term risks including osteoporosis, diabetes, and opportunistic infections—the ability to maintain remission without daily medication represents a profound improvement in quality of life. The data suggests that prula-cel can effectively replace a complex, highly toxic daily pharmaceutical cocktail with a single therapeutic intervention.[1][3]

The safety profile is what ultimately secured the FDA's outpatient alignment. The trial recorded no cases of immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome (IEC-HS). This severe hyperinflammatory condition recently caused three deaths in a Novartis autoimmune CAR-T trial and prompted Bristol Myers Squibb to pause its own CD19-targeted CAR-T program due to transient inflammatory events. Because prula-cel utilizes tissue-homing gamma delta T cells rather than circulating alpha-beta T cells, it appears to avoid triggering the systemic immune cascades that have plagued competing therapies. The absence of IEC-HS provides a critical competitive advantage as the industry searches for safer cellular chassis.[1]

Adicet also reported zero instances of neurotoxicity, clinically known as ICANS, and no cytokine release syndrome (CRS) exceeding Grade 2. Grade 1 or 2 CRS occurred in 25 percent of the 24 safety-evaluable patients, a rate considered highly manageable in a standard clinical setting. Infections affected 54 percent of the cohort, with severe Grade 3 or higher infections occurring in 8.3 percent of participants. The overall tolerability of the regimen convinced regulators that the therapy does not require the intensive, round-the-clock inpatient monitoring traditionally mandated for CAR-T infusions, drastically reducing the anticipated healthcare costs associated with the treatment.[1][3]

While the 12-month data demonstrates that naive B cells can repopulate without immediately triggering disease, researchers do not yet know if the rogue autoimmune response will eventually return years down the line. The upcoming pivotal trial will track whether the immune reset remains permanent across a much larger patient population, and whether the results hold true for lupus patients who do not yet suffer from kidney nephritis. If the remission proves durable, the off-the-shelf gamma delta platform could fundamentally alter the trajectory of severe autoimmune care, offering a one-time functional cure in place of lifelong, highly toxic disease management.[2]